Ulcerative colitis (UC) is a common gastrointestinal disorder in adults. Recent advances in
pathophysiology, immunology, and pharmaceutical science have resulted in a large number …

Advances in immunology, biotechnology, and phar-maceutical science have resulted in an
unprecedented number of medications with potential application to the treatment of Crohn’s …

This literature review and the recommendations therein were prepared for the American
Gastroenterological Association Clinical Practice Committee. The paper was approved by …

… P Rutgeerts, SB Hanauer, and BG Feagan collaborated to write the paper, with statistical
support from W Bao and clinical input from A Olson. GR Lichtenstein, LF Mayer, S Schreiber, JF …

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor
α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods Two …

Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized, …

Background Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective
maintenance therapy for patients with Crohn's disease without fistulas. It is not known …

Background The efficacy of vedolizumab, an α 4 β 7 integrin antibody, in Crohn's disease is
unknown. Methods In an integrated study with separate induction and maintenance trials, we …

Background Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and
interleukin-23, was evaluated as an intravenous induction therapy in two populations with …

Background Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have
potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further …